Key result
Higher MINE score severity stages are linked to progressively increased plasma NT-proBNP levels.
Why the study?
The relationship between the MINE score echocardiographic staging system and plasma NT-proBNP levels in dogs with MMVD was not well established.
Cross-Sectional (n=21)
No
p-value: p=<0.05
The MINE echocardiographic score correlates positively with NT-proBNP levels, suggesting their combined use may improve staging and prognostic assessment in dogs with myxomatous mitral valve disease.
Myxomatous mitral valve disease (MMVD) is the most common acquired cardiac disease in dogs. This study aimed to evaluate the relationship between the Mitral INsufficiency Echocardiographic (MINE) score, an echocardiographic staging system, and plasma NT-proBNP levels. Twenty-one client-owned dogs with MMVD were prospectively enrolled and underwent clinical, radiographic, electrocardiographic, and echocardiographic examinations. Dogs were classified according to MINE score. Plasma NT-proBNP concentrations were measured using a validated immunoassay. Results showed significant differences in echocardiographic parameters among severity groups and demonstrated a correlation between disease severity and NT-proBNP levels. These findings suggest that combining the MINE score with NT-proBNP measurement may improve staging accuracy, the association with MMVD severity, and clinical management of dogs affected by MMVD
No takes yet. Share an insight, caveat, or question.
Gambadauro et al. (2026) conducted a cross-sectional in Myxomatous mitral valve disease (MMVD) (n=21). Myxomatous mitral valve disease severity (MINE score) vs. Mild disease (MINE score) was evaluated on Plasma NT-proBNP concentration (p=<0.05). Plasma NT-proBNP concentrations increased significantly with worsening myxomatous mitral valve disease severity as classified by the MINE score.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: